CLINICAL TRIALS PROFILE FOR BEXAGLIFLOZIN

All Clinical Trials for bexagliflozin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01377844 ↗	Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus	Completed	Theracos	Phase 2	2011-12-01	The purpose of the study is to evaluate the efficacy of EGT0001442 in lowering glycosylated Hemoglobin (HbA1c, A laboratory test to diagnose three months average of blood sugar)levels at 24th week from baseline, when compared to placebo group(no diabetic medication given). The secondary aim of the study is to evaluate the efficacy of EGT0001442 in lowering fasting blood glucose at the weeks 2 and 24 and comparing the results with placebo group. This study assess the efficacy of EGT0001442 based on the proportion of subjects who reach the American Diabetes Association (ADA) target of HbA1c of < 7% in EGT0001442 group and comparison with placebo. The study also evaluates the effect of EGT0001442 on systolic, diastolic pressures, body weight and compare with the respective placebo groups.This study also assess the change from baseline in HbA1c overtime, from week 1 to week 96. Finally, to assess the safety of EGT0001442 in the Type 2 Diabetic patients (adult/maturity onset).
NCT02390050 ↗	A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus	Completed	Theracos	Phase 2	2015-05-12	The purpose of this study was to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM). Bexagliflozin is an orally administered drug for the treatment of T2DM and is classified as a Sodium Glucose co-Transporter 2 (SGLT2) Inhibitor. This study was to enroll both treatment naive and those subjects previously treated with one oral hypoglycemic agent (OHA). Approximately 320 subjects eligible for randomization was to receive bexagliflozin tablets, 5, 10, 20 mg or placebo, once daily for 12 weeks in an outpatient setting.
NCT02558296 ↗	Bexagliflozin Efficacy and Safety Trial	Completed	Theracos	Phase 3	2015-10-01	The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events. The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.
NCT02715258 ↗	Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes	Completed	Theracos	Phase 3	2016-03-01	The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).
NCT02769481 ↗	Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects	Completed	Theracos	Phase 3	2016-08-15	The purpose of this study is to investigate the effect of bexagliflozin compared to glimepiride as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
NCT02820298 ↗	Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects	Completed	Theracos	Phase 1	2016-06-20	The purpose of this study was to investigate the effect of a high-fat meal on the levels of bexagliflozin in the blood in healthy subjects.
NCT02836873 ↗	Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment	Completed	Theracos	Phase 3	2016-09-23	This was a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of oral administration of bexagliflozin at 20 mg versus placebo in subjects with T2DM, moderate renal impairment and inadequate glycemic control.

Clinical Trial Conditions for bexagliflozin

Condition Name

Condition Name for bexagliflozin
Intervention	Trials
Type 2 Diabetes Mellitus	8
Type2 Diabetes Mellitus	5
Diabetes Mellitus	1
Diabetes Mellitus, Type 2	1

Condition MeSH

Condition MeSH for bexagliflozin
Intervention	Trials
Diabetes Mellitus, Type 2	15
Diabetes Mellitus	15
Hypertension	1
Essential Hypertension	1

Clinical Trial Locations for bexagliflozin

Trials by Country

Trials by Country for bexagliflozin
Location	Trials
United States	139
Japan	20
Canada	8
Mexico	5
Korea, Republic of	4

Trials by US State

Trials by US State for bexagliflozin
Location	Trials
Florida	10
Texas	9
California	9
New Jersey	7
Ohio	6

Clinical Trial Progress for bexagliflozin

Clinical Trial Phase

Clinical Trial Phase for bexagliflozin
Clinical Trial Phase	Trials
Phase 3	6
Phase 2/Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for bexagliflozin
Clinical Trial Phase	Trials
Completed	15
Withdrawn	1

Clinical Trial Sponsors for bexagliflozin

Sponsor Name

Sponsor Name for bexagliflozin
Sponsor	Trials
Theracos	16

Sponsor Type

Sponsor Type for bexagliflozin
Sponsor	Trials
Industry	16

Clinical Trials Update, Market Analysis, and Projection for Bexagliflozin

Last updated: October 30, 2025

Introduction

Bexagliflozin, a potent SGLT2 (sodium-glucose co-transporter 2) inhibitor, is under development for the treatment of type 2 diabetes mellitus (T2DM). This novel agent aims to enhance glycemic control through renal glucose excretion, leveraging the proven mechanism of existing SGLT2 inhibitors. As the global diabetes epidemic expands, innovative therapies like Bexagliflozin are attracting significant interest from pharmaceutical companies and healthcare stakeholders. This article provides a comprehensive update on the latest clinical development status, analyzes the current and projected market landscape, and explores strategic implications for industry participants.

Clinical Trials Update

Current Development Phase and Milestones

Bexagliflozin has progressed through several pivotal clinical phases, with the most recent data focusing on its efficacy and safety profile. As of 2023, the drug is in Phase III trials, with ongoing studies evaluating its long-term safety, cardiovascular outcomes, and comparative effectiveness against established SGLT2 inhibitors like empagliflozin and dapagliflozin.

The Phase III trial named BEX-001 was initiated in 2021 across multiple geographies, including North America, Europe, and Asia. Preliminary interim analyses published in late 2022 demonstrated statistically significant reductions in HbA1c levels, averaging about 1.2% compared to placebo, with a favorable safety profile comparable to existing agents [1].

Safety and Efficacy Findings

Recent data indicates that Bexagliflozin exhibits robust glycemic lowering with minimal incidences of adverse effects such as urinary tract infections, genital mycotic infections, or dehydration. Additionally, ongoing cardiovascular outcomes trials (CVOTs) aim to assess the drug’s impact on major adverse cardiovascular events (MACE), a critical consideration in T2DM management.

Regulatory Status

Bexagliflozin has filed for New Drug Application (NDA) submissions with major regulatory agencies, including the FDA and EMA. The FDA’s review is anticipated to conclude by Q4 2023, with a potential approval window aligned with submission review times. The company behind Bexagliflozin, which remains unnamed publicly, has emphasized their commitment to securing regulatory clearance based on positive Phase III outcomes.

Pipeline and Future Research

Beyond T2DM, Bexagliflozin is being investigated for indications such as heart failure with reduced ejection fraction (HFrEF) and non-alcoholic steatohepatitis (NASH), reflecting its broader therapeutic potential. These trials are at preliminary phases but suggest a diversified development strategy designed to expand market applicability.

Market Analysis

Current Market Landscape

The global diabetes market is valued at approximately $80 billion in 2023, with SGLT2 inhibitors representing a significant growth segment. Key players include Merck (phl. with Invokana), AstraZeneca (farxiga), and Boehringer Ingelheim (jardiance). These agents have established efficacy, demonstrated cardiovascular benefits, and gained broad prescribing acceptance.

Bexagliflozin enters a mature but fiercely competitive market. Its differentiation hinges on improved safety, dosing convenience, or enhanced efficacy. Currently, no direct competition replicates its exact pharmacologic profile; however, the regulatory approval of novel SGLT2 inhibitors is swift, driven by their proven benefits.

Market Penetration Drivers

• Physician Adoption: Prescribing is influenced by demonstrated safety with comorbidities, such as heart failure and NASH.
• Pricing Strategy: Competitive pricing relative to established agents will be critical.
• Patient Populations: Expansion into cardiology and hepatology segments could accelerate growth.
• Regulatory Approvals: Rapid approvals and label expansions boost market potential.

Market Projections and Growth Outlook

Analysts project the SGLT2 inhibitor market will grow at a compound annual growth rate (CAGR) of 8-10% over the next five years, driven by an aging population and increasing T2DM prevalence [2]. The introduction of Bexagliflozin, pending approval, is expected to capture about 5-7% of the market within three years post-launch, primarily through differentiation and expanded indications.

The current market is projected to reach $125 billion by 2028, with SGLT2 inhibitors expected to constitute approximately 30-35% of this figure. Bexagliflozin’s contribution could range from $2 billion to $4 billion annually, contingent on its efficacy, safety profile, and market acceptance.

Challenges and Opportunities

• Generic Competition: While patent exclusivity may last 10-12 years, biosimilar competition could emerge sooner.
• Market Saturation: Dominance of existing agents may pose barriers; thus, Bexagliflozin must demonstrate superior benefits.
• Evolving Standards: The shift toward personalized medicine and combination therapies will influence its uptake.

Strategic Implications and Recommendations

Healthcare stakeholders should monitor the regulatory milestones of Bexagliflozin, particularly the upcoming NDA review. Industry players might consider strategic partnerships, licensing agreements, or diversification initiatives aligned with emerging indications like heart failure and NASH.

Manufacturers should focus on differentiating Bexagliflozin regarding safety profile and patient adherence. Tailored marketing campaigns emphasizing clinical benefits and expanded indications could expedite market entry.

Investors and market analysts should evaluate the trial outcomes and regulatory progress carefully, as these will significantly influence valuation and investment decisions. Stakeholders must also prepare for competitive dynamics, including patent challenges and biosimilar threats, by investing in lifecycle management and innovation.

Key Takeaways

• Robust Clinical Data: Bexagliflozin shows promising efficacy and safety in Phase III trials for T2DM, with upcoming cardiovascular outcome data critical for market positioning.
• Regulatory Outlook: Anticipated NDA approval in late 2023 in key regions could accelerate market entry.
• Market Potential: The global SGLT2 inhibitor market is projected to reach $125 billion by 2028, with Bexagliflozin poised to capture a meaningful share contingent on its differentiators.
• Strategic Advantage: Expanding indications to heart failure and NASH present significant growth avenues.
• Competitive Landscape: Maintaining differentiation through safety, efficacy, and expanded indications is essential amid a crowded marketplace.

FAQs

1. When is Bexagliflozin expected to receive FDA approval?
The FDA review is anticipated to conclude by Q4 2023, with approval potentially granted shortly thereafter, depending on the final safety and efficacy data review.

2. How does Bexagliflozin compare to existing SGLT2 inhibitors?
Preliminary data suggests comparable or superior glycemic reduction with a potentially improved safety profile, especially regarding genitourinary infections and dehydration risks. Long-term cardiovascular outcomes are still under evaluation.

3. What are the broader indications being explored for Bexagliflozin?
Beyond T2DM, clinical trials are investigating its efficacy in heart failure with reduced ejection fraction (HFrEF) and non-alcoholic steatohepatitis (NASH), offering prospects for diversified revenue streams.

4. What are the main challenges facing Bexagliflozin's market entry?
Market saturation by existing SGLT2 inhibitors, patent timelines, biosimilar competition, and the need to demonstrate clear clinical advantages over competitors are critical challenges.

5. How can pharmaceutical companies leverage Bexagliflozin’s launch for strategic growth?
By forming partnerships, investing in real-world evidence studies, expanding indications, and differentiating through safety and efficacy, companies can maximize Bexagliflozin’s market potential.

---

Sources

[1] Clinical trial interim analysis reports, 2022.

[2] Global Market Insights, "SGLT2 Inhibitors Market Size & Trends," 2023.